Shares in Repros Therapeutics Inc. spiked Friday on news that the FDA had cleared the company to perform a new study of Proellex, lifting a long-standing clinical hold that had been placed on its drug candidate for uterine fibroids and endometriosis. (BioWorld Today) Read More
